Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective

Journal of Medical Economics

Volumn 16, Issue 7, 2013, Pages 907-916

  Montouchet, C ^a   Ruff, L ^a   Balu, S ^b  

^a Medaxial Limited   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Budget impact; Cardiovascular disease; Hyperlipidemia; Rosuvastatin; Statin

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DRUG DOSE TITRATION; DRUG EFFICACY; DRUG LABELING; GOAL ATTAINMENT; HEALTH CARE COST; HEALTH ECONOMICS; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MANAGED CARE ORGANIZATION; PRESCRIPTION; SENSITIVITY ANALYSIS; TREATMENT DURATION;

ADULT; COSTS AND COST ANALYSIS; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MANAGED CARE PROGRAMS; MODELS, ECONOMIC; MYOCARDIAL INFARCTION; PYRIMIDINES; PYRROLES; SIMVASTATIN; STROKE; SULFONAMIDES; UNITED STATES;

EID: 84879762381     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.801350     Document Type: Article

References (44)

1. Hoyert D, Hu J. Deaths: preliminary data for 2011. Natl Vital Stat Rep 2011;61:1-65
2. Morbidity and mortality: 2012 chart book on cardiovascular, lung, and blood diseases. US Department of Health and Human Services: National Heart Lung and Blood Institute, 2012. Bethesda, MD. http://www.nhlbi.nih.gov/resources/ docs/2012-ChartBook-508.pdf. Accessed November 19, 2012
3. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011;123:933-44
4. Centers for Medicare and Medicaid Services. Health Care Financing Review: Medicare & Medicaid Statistical Supplement. Table 5.5: Discharges, total days of care, and program payments for medicare beneficiaries discharged from short-stay hospitals, by principal diagnoses within Major Diagnostic Classifications (MDCs): Calendar Year 2006. Baltimore, MD: Centers for Medicare and Medicaid Services, 2005. http://www.cms.hhs.gov/MedicareMedic-aidStatSupp/ downloads/2007Table5.5b.pdf. Accessed November 12, 2012
5. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-8
6. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47
7. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74
8. Kuklina EV, Shaw KM, Hong Y, et al. Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol-United States, 1999-2002 and 2005-200. MMWR 2011;60:109-14
9. Grundy SM. Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker Inc., 2000
10. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
11. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
12. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7
13. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-22
14. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92:152-60
15. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139:272-81
16. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-8
17. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
18. Faergeman O, Hill L, Windler E, et al. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholester-olemia: results from the ECLIPSE study. Cardiology 2008;111:219-28
19. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
20. New patient treatment patterns, dispensing fees and rebate amounts. Data on file. AstraZeneca LP, 2012
21. PHC Step Therapy Criteria: Statins. Physicians Health Choice. http://www.phccares.com/pdf/PHC%20Step%20Therapy%20Criteria%20Statins. pdf. Accessed November 19, 2012
22. Step therapy program. Medical Health Associates Health Plans, 2012. http://www.mahealthcare.com/step-therapy/StepTherapy-MedAssoc-2011.pdf. Accessed November 28, 2012
23. Prior Therapy Timeline Standardization: Oct-Dec 2012. Optima Health, 2012. Available at: http://public.optimahealth.com/Lists/OptimaForms Library/form-doc-timeline-for-step-edit-drugs.pdf. Accessed November 19, 2012
24. Ito MK, Lin JC, Morreale AP, et al. Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol. Am J Health Syst Pharm 2001;58:1734-9
25. Moisan J, Vaillancourt R, Grégoire JP, et al. Preferred hydroxymethylglutaryl-coenzyme A reductase inhibitors: treatment-modification program and outcomes. Am J Health Syst Pharm 1999;56:1437-41
26. Taylor AJ, Grace K, Swiecki J, et al. Lipid-lowering efficacy, safety, and costs of a large-scale therapeutic statin formulary conversion program. Pharmacotherapy 2001;21:1130-9
27. Meissner B, Dickson M, Shinogle J, et al. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a ministate managed Medicaid organization. J Manag Care Pharm 2006;12:331-40
28. Ara R, Pandor A, Stevens J, et al. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy? Eur J Prev Cardiol 2012;19:473-83
29. XE Universal Currency Converter. Mid-market exchange rates. 2013. www.xe.com. Accessed January 8, 2013
30. Kuklina EV, Yoon PW, Keenan NL. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006. JAMA 2009;302: 2104-10
31. Gandhi SK, Jä rbrink K, Fox KM, et al. Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice. Curr Med Res Opin 2009;25:2817-28
32. Willey VJ, Bullano MF, Shoetan NN, et al. Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin. Curr Med Res Opin 2010;26:121-8
33. Frolkis JP, Pearce GL, Nambi V, et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002;113:625-9
34. Data on file. AstraZeneca LP, 2013
35. Yale Health Pharmacy Benefit for Managerial & Professional and Faculty. New Haven, CT: Yale Health, 2013; http://yalehealth.yale.edu/yale- health-pharmacy-benefit-managerial-professional-and-faculty. Accessed January 3, 2013
36. Centers for Medicare and Medicaid Services. Physician Fee Schedule. Baltimore, MD: Centers for Medicare and Medicaid Services, 2012. www.cms.gov. Accessed June 12, 2012
37. Centers for Medicare and Medicaid Services. Clinical Laboratory Fee Schedule. Baltimore, MD: Centers for Medicare and Medicaid Services, 2012. www.cms.gov. Accessed June 12, 2012
38. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11:1-160, iii-iv
39. Charland SL, Cziraky MJ, Quimbo R, et al. Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events. J Clin Lipidol 2008;2:343-53
40. Ohsfeldt RL, Gandhi SK, Smolen LJ, et al. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. J Med Econ 2010;13:428-37
41. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012;125:e2-e220
42. Rublee DA, Burke JP. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice. Postgrad Med 2010;122:16-24
43. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 2012;56:374-80
44. Huse DM, Song X, Ozminkowski RJ, et al. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and Medicare populations: a data analysis. Clin Ther 2006;28:1425-42